Josef Bodor

Josef Bodor contributed to better understanding of the molecular mechanisms of cyclic adenosine monophosphate (cAMP) in regulation of immunity and tolerance (Bodor, J., Schmitt, E., Sitkovsky, M. Eds, Frontiers in Immunology, 8: 76, 2017). He studies the inhibitory effects of the second messenger cAMP on T-cell proliferation and effector functions. In collaboration with Shimon Sakaguchi at Kyoto University in Japan he outlined the role of inducible cAMP early repressor (ICER) in regulatory T cell-mediated suppression (Bodor et al. Eur J Immunol, 37: 884-895, 2007). His main contribution lies in description of the mechanism of cAMP-enabled ICER-mediated inhibition and its role in regulatory T cell-mediated suppression of interleukin-2 (IL-2) expression in vivo reported in Vaeth et al. Proc Natl Acad Sci USA, 108: 2480-2485, 2011. In these studies he devised successfully experiments leading to the final proof of the role of ICER in regulatory T cell-mediated transcriptional attenuation of numerous cytokines in the cells of immune synapse (reviewed in Bodor et al. Eur J Immunol, 42: 1375–1384, 2012).

Education

• Doctor of Philosophy (Ph.D.) Institute of Molecular Genetics, Prague, Czech Republic (1984 — 1990)
• Master of Science (M.Sc.) Masaryk University Brno (1982 — 1984)

Companies

• Senior Investigator BIOCEV - Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University (2017)
• Assistant Professor in Medicine Boston University (2002)
• Instuctor of Medicine Harvard Medical School (1996)
• Senior Investigator Institute of Experimental Medicine, Academy of Sciences of Czech Republic, EU Centre of Excellence (2014 — 2017)
• Visiting Professor University Medicine of the Johannes Gutenberg-University Mainz (2011 — 2013)
• Visiting Professor University of Wuerzburg (2008 — 2011)
• Assistant Professor in Pathology Columbia University in the City of New York (2005 — 2007)
• Senior Biotechnology Fellow National Cancer Institute (NCI) (1998 — 2003)
• Senior Postdoctoral Fellow National Cancer Institute (NCI) (1997 — 1999)